Alpine Immune Sciences
201 Elliott Ave West
Suite 230
Seattle
Washington
98119
United States
Tel: 206-788-4545
Website: http://alpineimmunesciences.com/
175 articles about Alpine Immune Sciences
-
Vertex Pharmaceuticals on Wednesday announced it is acquiring clinical-stage immunotherapy company Alpine Immune Sciences for $4.9 billion in cash, the largest acquisition so far this year.
-
Alpine Immune Sciences Shares Updated Clinical Data from Povetacicept in IgA Nephropathy
4/10/2024
Alpine Immune Sciences, Inc. (NASDAQ: ALPN) today shared updated clinical data for povetacicept in IgA nephropathy (IgAN) which will be presented as a late breaking poster at the World Congress of Nephrology (WCN) April 13-16, 2024 in Buenos Aires, Argentina.
-
Vertex Enters Into Agreement to Acquire Alpine Immune Sciences
4/10/2024
Vertex Pharmaceuticals Incorporated and Alpine Immune Sciences, Inc., a biotechnology company focused on discovering and developing innovative, protein-based immunotherapies, announced that the companies have entered into a definitive agreement under which Vertex will acquire Alpine for $65 per share or approximately $4.9 billion in cash.
-
Alpine Immune Sciences to Present Updated Clinical Data for Povetacicept in IgA Nephropathy at the World Congress of Nephrology 2024
4/1/2024
Alpine Immune Sciences, Inc. (NASDAQ: ALPN) has announced that the Company will present updated clinical data for povetacicept from RUBY-3, a phase 1b/2a study of povetacicept in autoimmune glomerulonephritis, including IgA nephropathy, in a late breaking poster presentation at the World Congress of Nephrology April 13-16, 2024 in Buenos Aires, Argentina.
-
Alpine Immune Sciences Presents New Translational Data on Povetacicept at the European Lupus Meeting 2024
3/21/2024
Alpine Immune Sciences, Inc. announced today that the Company presented new translational data for povetacicept (ALPN-303) at the SLEuro 14th European Lupus Meeting in Bruges, Belgium, March 19-22, 2024.
-
Alpine Immune Sciences to Participate in Upcoming H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual Conference
3/20/2024
Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases, today announced that the Company will participate in the H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual Conference.
-
Alpine Immune Sciences Provides Corporate Update and Full Year 2023 Financial Results
3/18/2024
Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases, today reported full year 2023 financial results and company highlights for the fourth quarter ended December 31, 2023.
-
Alpine Immune Sciences to Report Fourth Quarter and Full Year 2023 Financial Results
3/7/2024
Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases, today announced the Company will release fourth quarter and full year 2023 financial results on Monday, March 18, 2024, after the close of market.
-
Alpine Immune Sciences to Participate in Two Upcoming March 2024 Healthcare Conferences
2/26/2024
Alpine Immune Sciences, Inc., a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases, announced that the Company will participate in two upcoming healthcare conferences.
-
Alpine Immune Sciences to Participate in Two Upcoming February 2024 Healthcare Conferences
2/1/2024
Alpine Immune Sciences, Inc., a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases, announced that the Company will participate in two upcoming healthcare conferences.
-
Under the companies’ agreement, a previously disclosed option exercise fee of $75 million has been reduced to $10 million and the remaining pre-option development milestone has been removed.
-
Alpine Immune Sciences Announces Amendment of Acazicolcept Option and License Agreement with AbbVie
12/21/2023
Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases, announced today that the Company has amended the previously announced 2020 option and license agreement with AbbVie for acazicolcept.
-
Alpine Immune Sciences to Present at the 42nd Annual J.P. Morgan Healthcare Conference
12/18/2023
Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases, today announced that Mitchell Gold, M.D., Executive Chairman and Chief Executive Officer, will present at the 42nd Annual J.P. Morgan Healthcare Conference on Wednesday.
-
Alpine Immune Sciences to Participate in the Evercore ISI HealthconX Conference
11/20/2023
Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases, today announced that the Company will participate in the upcoming Evercore ISI HealthconX Conference, November 28-30, 2023.
-
Alpine Immune Sciences Presents New Translational Data on Povetacicept in Systemic Lupus Erythematosus at American College of Rheumatology Convergence 2023
11/15/2023
Alpine Immune Sciences, Inc. announced today that the Company presented new translational data for povetacicept (ALPN-303) in systemic lupus erythematosus (SLE) at the American College of Rheumatology Convergence 2023, November 10-15, 2023.
-
Alpine Immune Sciences Reports Third Quarter 2023 Financial Results
11/14/2023
Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases, today reported financial results and company highlights for the third quarter ended September 30, 2023.
-
Alpine Immune Sciences Presents New Translational Data on Acazicolcept in Systemic Lupus Erythematosus at American College of Rheumatology Convergence 2023
11/13/2023
Alpine Immune Sciences, Inc. announced today that the Company presented new translational data for acazicolcept (ALPN-101) in systemic lupus erythematosus (SLE) at the American College of Rheumatology Convergence 2023, November 10-15, 2023.
-
Alpine Immune Sciences Announces Pricing of $150 Million Public Offering
11/7/2023
Alpine Immune Sciences, Inc. (Nasdaq: ALPN) today announced the pricing of its underwritten public offering of 8,800,000 shares of its common stock and, in lieu of shares of common stock to certain investors, pre-funded warrants to purchase up to 3,200,000 shares of its common stock, pursuant to its existing shelf registration statement.
-
Alpine Immune Sciences Announces Proposed Public Offering - November 06, 2023
11/6/2023
Alpine Immune Sciences, Inc. announced that it has commenced an underwritten public offering of $150 million of shares of its common stock pursuant to its existing shelf registration statement.
-
Alpine Immune Sciences Presents New Preclinical Data on Povetacicept in Myasthenia Gravis at the American Association of Neuromuscular & Electrodiagnostic Medicine 2023 Annual Meeting
11/3/2023
Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases, announced the Company presented new preclinical data on povetacicept in myasthenia gravis at the American Association of Neuromuscular & Electrodiagnostic Medicine Annual Meeting (AANEM).